Investing for about 25 years and enjoy analyzing companies, especially special situations. I live in the US, have a PhD in the biological sciences, with about 20 years experience In clinical development and commercialiation/marketing of Therapeutic biologics, small molecules, and medical devices. As I have grown older, my philosophy has evolved from one of short-term trading, to finding stocks that can be held longer-term, preferably forever. I enjoy researching biotech stocks, but seldom invest here due to the volatility and risks. I rely on my own fundamental analysis but will also consider chart patterns when deciding opportunities to buy or sell. I always do my best to figure in investor & analyst psychology, and use basic financials to reassure me of my analysis (including mistakes) when volatility gets extreme. Do not consider myself to be an expert on technical analysis and as a scientist with training in statistics, am skeptical of that the historical movements of a stock can be used to reliably forecast buy/sell signals (if charting were that reliable as a predictive indicator, everyone would be using this to their advantage). In addition to looking at company's financials, I like to consider companies that are positioned to capitalize on changing demographics (growing per capita income in developing countries, aging of America, obesity epidemic, etc.), and strongly prefer companies with a wide economic moat. I frequently sell covered calls to mitigate and take adtvantage of market volatility. When I find a high conviction company that I want to own, not infrequently I will sell naked puts to reduce my cost basis and generate some cash flow.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
MaxSoar Group is an investment analysis team. We research and analyze a broad spectrum of financial assets including stocks, bonds, mutual funds, real estate properties, and private companies. Our knowledge and connections are especially strong in mainland China, Hong Kong, Taiwan, U.S. west, and Canada west. We also have knowledge in other eastern Asian countries such as Japan and Korea.
Assumes multiple responsibilities in a leading global fintech firm, with current role developing quantitative models and investment strategies with a wide spectrum of financial data, in particular the proprietary index business by collaborating with index providers and fund sponsors to build smart-beta indices and prototypes. Holds a Master on Molecular Biology and Biochemistry from Fudan University Medical School, MBA from Case Western Reserve University Business School and is a Chartered Financial Analyst (CFA) member of New York Chapter (NYSSA).
Individual investor, part-time, about 20 hours a week. Medical and research background has been helpful in my area of interest which is highly speculative biotechs - device, drugs, and drug delivery platforms.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Fredrik Arnold is my pen name. In 2012 I retired from doing quality service analysis for John Hancock Long Term Care Insurance in Boston then moved to North Carolina in 2013. My fascination with capital preservation, fixed fractional trading, and trading systems keeps me blogging for Seeking Alpha. Most of my articles focus on dividend yields and analyst mean 1 yr targets as stock trading indicators. These are essential tools for catching the most valuable dividend dogs.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
My primary focus is to invest in companies that pay substantial and growing dividends, with solid balance sheets and strong cash flows, that are trading at or under my calculated intrinsic value for the company. I supplement this with asset allocation, including bonds and options, as well as other investments such as MLPs.
Through my website, dividendmonk.com, I analyze dividend opportunities throughout the market. My individual stock portfolio listing is also available on my site. I'm an electronics engineer by profession.
Dr. Stephen Leeb is a recognized authority on the stock market, macroeconomic trends and commodities, especially oil and precious metals.
Dr. Leeb is founder of the Leeb Group, which publishes a line of financial newsletters including The Complete Investor, Leeb Income Performance Letter, Leeb Income Millionaire, Brain Trust Profits, Leeb's Real World Investing and Leeb's Aggressive Trader. His total readership exceeds 100,000. The Complete Investor newsletter has earned two awards for Editorial Excellence, as has Leeb Income Performance.
Dr. Leeb is also Chairman and Chief Investment Officer of a New York-based registered investment advisory firm. Dr. Leeb has been managing large cap growth portfolios since 1999.
Dr. Leeb sits on various boards sharing his strategic perspectives on financial markets and natural resources. Since 2008, Dr. Leeb has been a Director of Plain Sight Systems, a technology holding company centered at Yale University. Plain Sight owns a world-class patent portfolio in areas such as information organization/search, computational analytics, electro-optics, and spectroscopy. These technologies are licensed to Fortune 500 companies and used as part of private buyouts and venture spin-offs.
As part of Plain Sight, Dr. Leeb also sits on the board of Water Intelligence plc, a publicly listed company in England, operating in the water management space and Deep Markets Corporation, a division of Plain Sight developing next generation risk management applications.
Dr. Leeb is also Head of the Advisory Board of Leor Exploration & Production LLC (since 2006 - present) and a member of the advisory boards of Electrum USA Ltd. (since 2007) and Los Gatos. Each of these companies explore for natural resources, especially precious metals and energy.
Dr. Leeb is the author of eight books on investments and financial trends. His latest book, Red Alert: How China's Growing Prosperity Threatens the American Way of Life (Business Plus, 2012) predicts China's coming global domination.
An earlier book, The New York Times best seller, The Coming Economic Collapse: How You Can Thrive When Oil Costs $200 a Barrel (Warner Books, 2006), predicted that tightness in global energy supplies would cause the American economy to oscillate between periods of recession and high inflation this century.
Dr. Leeb’s best seller, The Oil Factor: Protect Yourself and Profit from the Coming Energy Crisis (Warner Books, 2004), outlined the relationship between oil prices and stock market performance and accurately predicted the subsequent surge in oil prices. The book was rated among the top investment books of the year by Stock Trader's Almanac 2005.
His earlier best seller, Defying the Market: Profiting in the Turbulent Post-Technology Market Boom (McGraw-Hill; 1999) predicted the collapse of technology stocks and the growing importance of oil, and other hard assets during the 21st century. The book was selected by Library Journal as one of the Best Business Books of 1999.
His first book Getting in on the Ground Floor (Putnam, 1986) predicted the secular bull market in financial assets and the fall in inflation. The book was a main selection of the Money Book Club.
Dr. Leeb earned his Bachelor's degree in Economics from the University of Pennsylvania's Wharton School of Business. He then completed both a Master's degree in Mathematics and a Ph.D. in Psychology at the University of Illinois.
Jon Slotnick is a stock analyst and trader who currently provides stock analysis and alerts to several financial websites. He has also worked as a freelance copywriter for TD Ameritrade's active trader initiatives, and written a series of financial literacy DVDs for New York Times bestselling author Julie Stav. He has a Masters Degree in Journalism from UC Berkeley.
Welcome to my author's site.
I hope you find my articles interesting and informative.
A man-with-a-plan, I am utilizing knowledge gained from my business degree 25+ years in the business world and a similar number of years of investing experience, to manage my investments.
I have created and maintain a stable and growing portfolio of individual US listed dividend growth stocks, over 30% of which are non-US based but headquartered in Canada, Great Briton, the Netherlands and Australia.
I believe that asset allocation is the primary decision an investor must make considering his objectives, time frame and risk tolerance. I am fully invested and 90% of that is in stock.
I believe that the small individual investor is often best served by low cost index funds. Stock picking, attempted market timing and frequent trading usually work to the disadvantage of the average small investor. However, you may define small as you like and nothing prevents any investor from emulating the market greats of our time such as Warren Buffett or Peter Lynch. Greater rewards can be obtained by buying and holding individual securities if one has background, the interest, the time and the disciplne to do so in an effective way.
There are many ways to make money in the stock and bond markets. My approach to is to take ownership positions in successful large cap companies and hold them a number of years. Dividend Growth Investing is a conservative approach which involves lower than average risks and higher than average rewards.
My writing experience began when I was a senior in high school. I was a local stringer for Maine's largest newspaper and covered school and amatuer sports. Concurrent with a successful career in the business world I wrote magazine articles, journal articles, short fiction, poetry and a devotional book.
A long time student of security markets I immensely enjoy the opportunity to write for Seeking Alpha, which is a very high quality well run organization with excellent editorial support. It is also possibly the best business forum on the internet and I am proud to be a part of it.
Most of my articles focus on several topics:
Income Portfolio Strategy
Canadian Banks and Telecoms
Best regards and good luck!
-- Bob J
Ingrid R. Hendershot, CFA is the founder and president of Hendershot Investments, a woman-owned registered investment adviser based in Virginia. With more than twenty-five years of investing experience, Ingrid invests in high-quality companies at reasonable valuations and holds them for the long term. This strategy is applied to companies with various market capitalizations.
Jeff Paul has been investing since his teen years, though his professional career has been in software engineering and education. His math classes participated in online stock market challenges, providing an opportunity to share his enthusiasm for investing with his students and the chance for them to learn the fundamentals and try to identify the next big stock (they found Google). He recently completed an MBA at Portland State University with a focus on finance, and is currently a Senior Investment Analyst at a wealth management firm.
Steve Cook received his education in investments from Harvard, where he earned an MBA, New York University, where he did post graduate work in economics and financial analysis and the CFA Institute, where he earned the Chartered Financial Analysts designation in 1973. His 46 years of investment experience includes institutional portfolio management at Scudder. Stevens and Clark and Bear Stearns, managing a risk arbitrage hedge fund and an investment banking boutique specializing in funding second stage private companies. Through his involvement with Investing for Survival and Seeking Alpha, Steve hopes that his experience can help other investors build their wealth while avoiding tough lessons that he learned the hard way.
Red Acre applies value investing principles to mirco-cap and binary event investing.
Our Chief Investment Officer is Rajesh Patel. Prior to Red Acre, Rajesh was a Member of Technical Staff with the Massachusetts Institute of Technology, (MIT) Lincoln Laboratory where he analyzed the strategic value of emerging technologies to enhance the capabilities of the U.S. Military. Rajesh holds a Ph.D. in Applied Physics from the University of California, Davis, a Master's in Environmental Science from Rice University and bachelors degrees in both Physics and English from the University of Connecticut.
Red Acre's investment style is to look for opportunities where the intrinsic value of a stock is likely to go through a dramatic transition due to some future event about which we can predict an outcome relying on our research and due diligence experience. We are patient investors and are comfortable with having time horizons of several months to over a year for our investment thesis to fully play out.
I am now retired from the US pharma industry having spent over 33 years in the Mid-Atlantic corridor in Sales(Hospital mainly), Scientific Relations and Managed Care/LTC. I worked at BMY, Bayer/Miles Labs and SGP/MRK prior to early retirement..
Today I enjoy investing in Bio-Pharmas mostly, because it is what I know best!
I invest mostly in large companies such as BMY, PFE, MRK, GSK, and JNJ (love the divis) but I like the up and coming Bios like CLDX. Cancer and Immunotherapy intrigues me..so I have made that a major consideration since 2008....With BARDA,the GAIN act and QDIP Ive come to appreciate the Antibiotic cos.and have made them a major component of my LT strategy to build wealth while in Retirement....Ive invested in Trius(TSRX),CBST, CEMP, DRTX, TTPH, CTIX and just added AKAO.....
I manage personal monies and some family members..gratis of course!
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
As I am helping my partner of 20+ years in her battle against stage IV cancer, I don't really have the time to be very involved with comments. Likewise, I may not be able to update a particular story/situation/investment idea in an especially timely fashion.
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).